Synthesis of pyrazoles and isoxazoles as potent αvβ3 receptor antagonists
摘要:
We describe a series of pyrazole and isoxazole analogs as antagonists of the 043 receptor. Compounds showed low to sub-nanomolar potency against alpha(v)beta(3), as well as good selectivity against alpha(IIb)beta(3). In HT29 cells, most analogs also demonstrated significant selectivity against alpha(v)beta(6). Several compounds showed good pharmacokinetic properties in rats, in addition to anti-angiogenic activity in a mouse corneal micropocket model. Compounds were synthesized in a straightforward manner from readily available glutarate precursors. (c) 2006 Elsevier Ltd. All rights reserved.
Synthesis of pyrazoles and isoxazoles as potent αvβ3 receptor antagonists
摘要:
We describe a series of pyrazole and isoxazole analogs as antagonists of the 043 receptor. Compounds showed low to sub-nanomolar potency against alpha(v)beta(3), as well as good selectivity against alpha(IIb)beta(3). In HT29 cells, most analogs also demonstrated significant selectivity against alpha(v)beta(6). Several compounds showed good pharmacokinetic properties in rats, in addition to anti-angiogenic activity in a mouse corneal micropocket model. Compounds were synthesized in a straightforward manner from readily available glutarate precursors. (c) 2006 Elsevier Ltd. All rights reserved.
[EN] PYRAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES<br/>[FR] COMPOSES DE PYRAZOLE EN TANT QU'ANTAGONSITES DES RECEPTEURS DE L'INTEGRINE
申请人:PHARMACIA CORP
公开号:WO2004058761A1
公开(公告)日:2004-07-15
The present invention relates to pharmaceutical compositions comprising compounds of the Formula (I), and methods of selectively inhibiting or antagonizing the αVβ3 and/or the α Vβ5 integrin without significantly inhibiting the α Vβ6 integrin.
Pyrazole compounds as integrin receptor antagonists derivatives
申请人:Penning D. Thomas
公开号:US20050004200A1
公开(公告)日:2005-01-06
The present invention relates to a class of compounds represented by the Formula I
or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the α
V
β
3
and/or the α
V
β
5
integrin without significantly inhibiting the α
V
β
6
integrin.